Streetbeat News

Analyst Ratings

CRSP

Needham analyst Gil Blum has reiterated a 'Buy' rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained an $88 price target.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:30 am

HRMY

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $53.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:28 am

LVLU

Telsey Advisory Group has reiterated its 'Market Perform' rating on Lulus Fashion Lounge (NASDAQ:LVLU) and maintained its price target of $3.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:25 am

XPO

Raymond James analyst Patrick Tyler Brown maintains an 'Outperform' rating on XPO Logistics (NYSE:XPO) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:21 am

THC

Raymond James analyst John Ransom maintains a Strong Buy rating on Tenet Healthcare (NYSE:THC), but has lowered the price target from $95 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:19 am

AMD

BGFV

CLS

LXRX

MTCH

PAYC

PYCR

YUMC

ZYXI

Several US-listed companies including Paycom Software, Big 5 Sporting Goods Corporation, Yum China Holdings, Paycor HCM, Lexicon Pharmaceuticals, Match Group, Celestica, Zynex, and Advanced Micro Devices recorded losses in pre-market trading on Wednesday. This was due to various reasons such as worse-than-expected Q3 results, downgraded stocks, and issued FY23 revenue guidance below estimates.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 10:17 am

NBIX

Raymond James analyst Danielle Brill maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $135 to $145.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:17 am

MPC

Raymond James analyst Justin Jenkins maintains a Strong Buy rating on Marathon Petroleum (NYSE:MPC) and raises the price target from $171 to $175.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:14 am

MSCI

Raymond James analyst Patrick O'Shaughnessy has maintained an 'Outperform' rating on MSCI (NYSE:MSCI) but lowered the price target from $577 to $533.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:12 am

HRMY

Raymond James analyst Danielle Brill maintains an 'Outperform' rating on Harmony Biosciences (NASDAQ:HRMY) and raises the price target from $26 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:06 am